TABLE 1.
Demographic and clinical characteristics of the cohort participantsa
| Parameter | Result for group (n = 125) |
||
|---|---|---|---|
| Control (n = 51) | MCI (n = 27) | AD (n = 47) | |
| Sex, % (no. female/total) | 45 (23/51) | 41 (11/27) | 49 (23/47) |
| Age, mean ± SD yr | 67 ± 5.3 | 69.2 ± 6.4 | 71.4 ± 5.1 |
| Education, mean ± SD yr | 7.2 ± 4.1 | 10.4 ± 5.2 | 4.4 ± 4.1 |
| MMSE, mean ± SD | 27.1 ± 1.7 | 25.4 ± 2.7 | 16.9 ± 5.7 |
| CDR, % (no./total) | |||
| 0 | 100 | 0 | 0 |
| 0.5 | 0 | 100 (27/27) | 29.8 (14/47) |
| 1 | 0 | 0 | 31.9 (15/47) |
| 2 | 0 | 0 | 29.8 (14/47) |
| 3 | 0 | 0 | 8.5 (4/47) |
| Aβ1–42/p-tau (pg/mL) | NA | NA | 5.97 ± 3.7 (n = 14) |
| Aβ1–42/t-tau (pg/mL) | NA | NA | 0.91 ± 0.6 (n = 14) |
| Medication, % (no./total) | |||
| AA | NA | 37 (10/27) | 27.6 (13/47) |
| Add | NA | 81 (22/27) | 87 (41/47) |
| Adep | NA | 66.7 (18/27) | 27.6 (13/47) |
| AE | NA | 18.5 (5/27) | 8.5 (4/47) |
| Aht | NA | 48 (13/27) | 29.8 (14/47) |
| Apsik | NA | 11.1 (3/27) | 21.2 (10/47) |
| Adiab | NA | 29.6 (8/27) | 19.1 (9/47) |
| PP | NA | 7.4 (2/27) | 6.3 (3/47) |
a
Shown are the demographic characteristics, cognitive performance, concentrations of cerebrospinal fluid biomarkers (Aβ1–42, t-tau, and p-tau), and groups of medicine used by the participants. MCI, mild cognitive impairment group; AD, Alzheimer's disease group; MMSE, Mini-Mental State Exam (MMSE); CDR, Clinical Dementia Rating; AA, antiaggregant; Add, AD treatment; Adep, antidepressant; AE, antiepileptic; Aht, antihypertensive; Apsik, antipsychotic; Adiab, antidiabetic; PP, proton pump inhibitor; NA, not applicable; Aβ1–42, amyloid beta peptide; p-tau, Thr-phosphorylated tau; t-tau, total tau.